PreSeries A Funding Round

VerImmune Inc., a biotechnology company, has successfully closed a $4.5 million PreSeries A financing round. The funding will be utilized to advance the development of their lead product candidate, VERI101, towards clinical trials. VERI101 is a Firstinclass cancer immunotherapy leveraging the Virusinspired Particle (ViP) technology to redirect preexisting immune memory from CMV infection towards tumors…